Calmark recruits Michael Lund to key position as QA/RA Director
Calmark Sweden AB has hired Michael Lund who will assume position as Quality Assurance and Regulatory Affairs Director, a role which he has held on a consultancy basis since 2016. Michael is part of Calmark's management team and is responsible for project management and quality assurance of the product development, as well as certification and registration of the products in different markets.
Michael Lundh has a wealth of experience from Project Management and QA/RA activities and has been working as a self-employed consultant since 2003. Michaels background is electrical engineering and digital ASIC/FPGA design. His focus shifted towards Project Management and Medical devices and in recent years he has been working with projects at for example Hemcheck Sweden AB, Vivoline Medical AB and Arjo Hospital Equipment.
At Calmark, Michael has been responsible for the overarching project management of the development projects, the production start-up, and the establishment of quality management systems.
"I have accompanied Calmark on its exciting journey for several years, and I appreciate the company's mission and corporate culture - not to mention the highly qualified team," says Michael Lundh. "I look forward to completing my mission all the way through!"
"Michael Lundh has been an important key person at Calmark since 2016; his competence in CE marking processes and regulatory systems has been a critical factor in our achievements thus far. We will require his skills in the longer term, particularly for the future registration of our products around the world. I am very pleased that we have been able to recruit Micke!" says Anna Söderlund, CEO of Calmark.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.